These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38234671)

  • 1. Comparison of the anti-inflammatory and antilipidemic activity of diosmin and saroglitazar in a model of nonalcoholic fatty liver induced by a high-fat diet in Wistar rats.
    Afarin R; Dinarvand N; Jaberian Asl B; Orak G; Shakerian E; Bineshfar F; Ahangarpour A
    Iran J Basic Med Sci; 2024; 27(2):241-246. PubMed ID: 38234671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Curcumin and saroglitazar attenuate diet-induced nonalcoholic steatohepatitis by activating the Nrf2 pathway and suppressing ERK1/2 signaling.
    Afarin R; Dinarvand N; Azizi Dariuni H; Orak G; Jaberian Asl B; Azizi R; Khedri A
    Iran J Basic Med Sci; 2024; 27(8):1015-1022. PubMed ID: 38911240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis.
    Akbari R; Behdarvand T; Afarin R; Yaghooti H; Jalali MT; Mohammadtaghvaei N
    BMC Pharmacol Toxicol; 2021 Oct; 22(1):53. PubMed ID: 34593018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin treatment reverses high fat diet- induced non-alcoholic fatty liver diseases and dyslipidemia by stimulating multiple antioxidant and anti-inflammatory pathways.
    Yasmin T; Rahman MM; Khan F; Kabir F; Nahar K; Lasker S; Islam MD; Hossain MM; Hasan R; Rana S; Alam MA
    Biochem Biophys Rep; 2021 Dec; 28():101168. PubMed ID: 34825068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models.
    Jain MR; Giri SR; Bhoi B; Trivedi C; Rath A; Rathod R; Ranvir R; Kadam S; Patel H; Swain P; Roy SS; Das N; Karmakar E; Wahli W; Patel PR
    Liver Int; 2018 Jun; 38(6):1084-1094. PubMed ID: 29164820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The protective effects of the β3 adrenergic receptor agonist BRL37344 against liver steatosis and inflammation in a rat model of high-fat diet-induced nonalcoholic fatty liver disease (NAFLD).
    Wang Z; Li S; Wang R; Guo L; Xu D; Zhang T; Xu Y; Wang W; Wang M; Gan Z; Wang X
    Mol Med; 2020 Jun; 26(1):54. PubMed ID: 32503411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Saroglitazar in Nonalcoholic Fatty Liver Patients With Diabetic Dyslipidemia-A Prospective, Interventional, Pilot Study.
    Rajesh NA; Drishya L; Ambati MMR; Narayanan AL; Alex M; R KK; Abraham JJ; Vijayakumar TM
    J Clin Exp Hepatol; 2022; 12(1):61-67. PubMed ID: 35068786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BabaoDan attenuates high-fat diet-induced non-alcoholic fatty liver disease via activation of AMPK signaling.
    Sheng D; Zhao S; Gao L; Zheng H; Liu W; Hou J; Jin Y; Ye F; Zhao Q; Li R; Zhao N; Zhang L; Han Z; Wei L
    Cell Biosci; 2019; 9():77. PubMed ID: 31548878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intervention of Catalpol on High-fat Diet Induced Nonalcoholic Fatty Liver Disease in Mice].
    Tian X; Xiong Q; Chen L; Wen JR; Ru Q
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Dec; 41(6):746-755. PubMed ID: 31907123
    [No Abstract]   [Full Text] [Related]  

  • 10. The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease.
    Kumar DP; Caffrey R; Marioneaux J; Santhekadur PK; Bhat M; Alonso C; Koduru SV; Philip B; Jain MR; Giri SR; Bedossa P; Sanyal AJ
    Sci Rep; 2020 Jun; 10(1):9330. PubMed ID: 32518275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prenatal ethanol exposure programs an increased susceptibility of non-alcoholic fatty liver disease in female adult offspring rats.
    Shen L; Liu Z; Gong J; Zhang L; Wang L; Magdalou J; Chen L; Wang H
    Toxicol Appl Pharmacol; 2014 Jan; 274(2):263-73. PubMed ID: 24275070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Saroglitazar and Hepano treatment offers protection against high fat high fructose diet induced obesity, insulin resistance and steatosis by modulating various class of hepatic and circulating lipids.
    Sarkar S; Kumari D; Gupta SK; Sharma V; Mukhi S; Kamboj P; Sasibhushan V; Rai RK; Jatavallabhula SL; Mahajan D; Kumar Y; Kumar A; Dikshit M
    Biomed Pharmacother; 2021 Dec; 144():112357. PubMed ID: 34794234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.
    Honda A; Kamata S; Satta C; Machida Y; Uchii K; Terasawa K; Nemoto A; Oyama T; Ishii I
    Biol Pharm Bull; 2021; 44(9):1210-1219. PubMed ID: 34471049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polychlorinated biphenyl 153 is a diet-dependent obesogen that worsens nonalcoholic fatty liver disease in male C57BL6/J mice.
    Wahlang B; Falkner KC; Gregory B; Ansert D; Young D; Conklin DJ; Bhatnagar A; McClain CJ; Cave M
    J Nutr Biochem; 2013 Sep; 24(9):1587-95. PubMed ID: 23618531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Water extract from artichoke ameliorates high-fat diet-induced non-alcoholic fatty liver disease in rats.
    Deng A; Liu F; Tang X; Wang Y; Xie P; Yang Q; Xiao B
    BMC Complement Med Ther; 2022 Nov; 22(1):308. PubMed ID: 36424606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL/6 mice fed on choline deficient, l-amino acid- defined, high-fat diet.
    Giri SR; Bhoi B; Trivedi C; Rath A; Rathod R; Sharma A; Ranvir R; Kadam S; Ingale K; Patel H; Nyska A; Jain MR
    BMC Cancer; 2023 Jan; 23(1):59. PubMed ID: 36650455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diosmin ameliorates inflammation, insulin resistance, and fibrosis in an experimental model of non-alcoholic steatohepatitis in rats.
    Gerges SH; Wahdan SA; Elsherbiny DA; El-Demerdash E
    Toxicol Appl Pharmacol; 2020 Aug; 401():115101. PubMed ID: 32512072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Esculeogenin A, a Glycan from Tomato, Alleviates Nonalcoholic Fatty Liver Disease in Rats through Hypolipidemic, Antioxidant, and Anti-Inflammatory Effects.
    Al Jadani JM; Albadr NA; Alshammari GM; Almasri SA; Alfayez FF; Yahya MA
    Nutrients; 2023 Nov; 15(22):. PubMed ID: 38004149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventive Effect of Citrus aurantium Peel Extract on High-Fat Diet-Induced Non-alcoholic Fatty Liver in Mice.
    Han HY; Lee SK; Choi BK; Lee DR; Lee HJ; Kim TW
    Biol Pharm Bull; 2019; 42(2):255-260. PubMed ID: 30713255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kangtaizhi Granule Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats and HepG2 Cells via AMPK/mTOR Signaling Pathway.
    Zhang J; Du H; Shen M; Zhao Z; Ye X
    J Immunol Res; 2020; 2020():3413186. PubMed ID: 32884949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.